MedTrace Logo

Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients

NCT01359800 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 531

Last updated 2016-03-04

No results posted yet for this study

Summary

Tat is a key HIV regulatory protein produced very early after infection, prior to virus integration, and necessary for viral gene expression, cell-to-cell virus transmission and disease progression. Previous studies in natural HIV infection, indicated that the presence of a Tat-specific immune response correlates with a lower incidence and reduced risk of progression to AIDS as compared to anti-Tat negative individuals suggesting that an immune response to Tat may exert a protective role and control the progression to AIDS in vivo.

On the basis of the above mentioned consideration, the present study was directed at investigating the seroprevalence of anti-Tat antibodies in HIV-infected South African patients.

Conditions

  • HIV Infection

Sponsors & Collaborators

  • Italian Ministry of Foreign Affairs - Dir. Gen. for Cooperation and Development

    collaborator UNKNOWN

  • Barbara Ensoli, MD

    lead OTHER

Principal Investigators

  • Barbara BE Ensoli, MD PhD · Istituto Superiore di Sanità

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-02-28
Completion
2013-07-31

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359800 on ClinicalTrials.gov